NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









VarmX

VarmX

Private
LeidenHealthcare & Life Scienceshttps://varmx.com/

Last Round

M&A

Sep 16, 2024

Total Funding Raised

$87.13M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

VarmX is a biotechnology company that develops therapeutic drugs designed to restore blood clotting in bleeding patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

anticoagulation reversaldirect oral anticoagulantsDOACstherapeutic proteinsrecombinant factor Xahemostasisbleeding reversal agentbiotechnologyclinical-stage biotechprotein engineeringantidotedrug developmentemergency medicinebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VarmX Comparables

Compare VarmX with similar companies based on industry and business-model similarity.

VarmX comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Perosphere Pharmaceuticals Inc.
86%
AstraZeneca
82%
Takeda
74%

VarmX Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&ASep 16, 2024
Series B ExtensionMay 25, 2023
GrantOct 21, 2021
Series BJul 8, 2020
DebtJul 2, 2018
Series A
Jul 2, 2018

Key People

Founding team and executive leadership

John Glasspool

Chief Executive Officer

Executive Team

Paul Roos

Chief Financial Officer

Executive Team

Martijn Negen MSc

Chief Operating Officer

Executive Team

VarmX Investors

Notable investors and investment history

VarmX investors
InvestorRounds
Lundbeck FoundationSeries B
European Innovation Council FundGrant, Series B Extension
EQT Life SciencesSeries B Extension
Lundbeckfonden BioCapitalSeries B Extension
Ysios CapitalSeries B Extension, Series B
BioGeneration VenturesSeries B Extension, Series B, Seed, Series A
Netherlands Enterprise AgencyDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors increased 50% MoM.

VarmX Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

VarmX Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VarmX's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeiden
Employee Range32
Year Founded2016
Last FundingSep 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.